Real-World Persistence After Starting Bictegravir- or Dolutegravir-Based Regimens Among Adults Aged ≥50 Years with HIV in the United States

B/F/TAF was associated with higher persistence than other ART regimens among older PWH. Findings underscore the importance of tailored ART selection to address the unique challenges faced by older PWH.